Loading people...
Cheryl Zimberlin is an investor at M Ventures, the corporate venture capital fund of Merck KGaA, Darmstadt, Germany. She focuses on strategic investments in innovative life science and healthcare startups.
Cheryl Zimberlin invests in groundbreaking companies within the life science and healthcare sectors. Her focus areas include biotechnology, digital health, medical devices, novel therapeutics, precision medicine, gene therapies, immunology, oncology, and neurodegenerative diseases.
Cheryl Zimberlin works at M Ventures, which is the corporate venture capital arm of Merck KGaA, Darmstadt, Germany. M Ventures operates globally, seeking out innovative investment opportunities.
Cheryl Zimberlin is an Investment Director at M Ventures, the corporate venture capital arm of Merck KGaA, based in Amsterdam, Netherlands. She has completed 14 total investments across early and mid-stage venture opportunities, specializing in biotechnology, oncology, and immunotherapies. Zimberlin serves as a board director or observer for several therapeutics startups, including ImmuneBridge, Storm Therapeutics, iOnctura, and Precirix, where she represented M Ventures in an €80 million Series B financing round during March 2022. Previously, she acted as a board observer for Calypso Biotech, which was acquired by Novartis in January 2024 for a $250 million upfront payment and up to $425 million in potential future milestones. Her current focus remains on leveraging her PhD in Molecular Biology and Oncology from the Netherlands Cancer Institute to identify and support innovative, early-stage European life sciences companies.
Cheryl Zimberlin is a key investor at M Ventures, the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany. In her capacity, Cheryl plays a crucial role in identifying, evaluating, and investing in innovative startups that are poised to make a significant impact in the life science and healthcare industries. Her work is instrumental in fostering the growth of companies developing cutting-edge technologies and solutions, aligning with Merck's commitment to scientific discovery and patient well-being.
M Ventures is renowned for its global investment strategy, backing companies that are at the forefront of scientific and technological advancement. Cheryl's investment focus areas typically span a broad spectrum within healthcare and life sciences, including but not limited to biotechnology, digital health, medical devices, and novel therapeutic platforms. She seeks out opportunities in areas such as precision medicine, gene therapies, immunology, oncology, and neurodegenerative diseases, as well as disruptive digital health solutions that enhance patient care and operational efficiency. Her expertise helps M Ventures to build a robust portfolio of promising ventures that complement Merck's core business areas and future growth strategies.
While specific details of Cheryl Zimberlin's career background are often kept private, investors at M Ventures typically possess a strong foundation in science, medicine, or business, often coupled with extensive experience in venture capital, corporate development, or the pharmaceutical and biotech industries. This background equips them with the deep industry knowledge and strategic foresight necessary to identify high-potential companies and guide them through their growth phases. Her role involves not only capital allocation but also providing strategic guidance and leveraging Merck's vast resources to support portfolio companies.
Cheryl's contributions are vital to M Ventures' mission of investing in groundbreaking science and technology. While individual notable investments are part of M Ventures' extensive portfolio and often not attributed to a single investor publicly, her work contributes to the fund's overall success in backing companies that are developing next-generation treatments, diagnostic tools, and digital health platforms. Her efforts help to bring innovative solutions from concept to commercialization, ultimately benefiting patients and advancing the global healthcare landscape. Through her strategic investments, Cheryl Zimberlin helps to shape the future of healthcare and life sciences, driving innovation and creating value for both M Ventures and its portfolio companies.
